Literature DB >> 25753925

Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

T Matthes1, T McKee2, I Dunand-Sauthier3, B Manfroi4, S Park5, J Passweg6, B Huard1,4.   

Abstract

Multiple myeloma (MM) is a non-curable tumor developing in the bone marrow (BM). The BM microenvironment rich in hematopoietic precursors is suspected to have a role in MM development. Here we show that a proliferation-inducing ligand (APRIL) mediated in vivo MM promotion. In MM-infiltrated BM, APRIL originated from differentiating myeloid cells with an expression peak in precursor cells. Notably, APRIL expression stayed stable in BM despite MM infiltration. The pool of APRIL-producing cells changed upon MM infiltration. Although CD16(+) mature myeloid cells constituted about half of the APRIL-producing cells in healthy BM, CD16(-) Elastase(+) myeloid precursor cells were predominant in MM-infiltrated BM. Myeloid precursor cells secreted all the APRIL they produced, and binding of secreted APRIL to MM cells, strictly dependent of heparan sulfate carried by CD138, resulted in an in situ internalization by tumor cells. This indicated APRIL consumption by MM in BM. Taken together, our data show that myelopoiesis dysregulation characterized by an increased proportion of precursor cells occurs in MM patients. Such dysregulation correlates with a stable expression of the MM-promoting factor APRIL in infiltrated BM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25753925     DOI: 10.1038/leu.2015.68

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  45 in total

Review 1.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow.

Authors:  Oliver Winter; Katrin Moser; Elodie Mohr; Dimitra Zotos; Henriette Kaminski; Martin Szyska; Katrin Roth; David M Wong; Christof Dame; David M Tarlinton; Harald Schulze; Ian C M MacLennan; Rudolf A Manz
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 3.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

4.  APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.

Authors:  John Quinn; Janet Glassford; Laura Percy; Philippa Munson; Teresa Marafioti; Manuel Rodriguez-Justo; Kwee Yong
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

5.  Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.

Authors:  L E Roeker; D R Larson; R A Kyle; S Kumar; A Dispenzieri; S V Rajkumar
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

6.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

Authors:  Bart Barlogie; Guido Tricot; Jeff Haessler; Frits van Rhee; Michele Cottler-Fox; Elias Anaissie; James Waldron; Mauricio Pineda-Roman; Raymond Thertulien; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; John Crowley; Jeffrey Sawyer
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

7.  Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.

Authors:  Iris Breitkreutz; Marc S Raab; Sonia Vallet; Teru Hideshima; Noopur Raje; Dharminder Chauhan; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

8.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

9.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Developmental changes in heparan sulfate expression: in situ detection with mAbs.

Authors:  G David; X M Bai; B Van der Schueren; J J Cassiman; H Van den Berghe
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  8 in total

1.  Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; B Manfroi; A Zeller; I Dunand-Sauthier; B Bogen; B Huard
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

2.  Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy.

Authors:  Masahiro Muto; Benoit Manfroi; Hitoshi Suzuki; Kensuke Joh; Masaaki Nagai; Sachiko Wakai; Christian Righini; Masayuki Maiguma; Shozo Izui; Yasuhiko Tomino; Bertrand Huard; Yusuke Suzuki
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

3.  B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Expert Opin Biol Ther       Date:  2019-07-11       Impact factor: 4.388

4.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

5.  Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells.

Authors:  Marion Chapellier; Pablo Peña-Martínez; Ramprasad Ramakrishnan; Mia Eriksson; Mehrnaz Safaee Talkhoncheh; Christina Orsmark-Pietras; Henrik Lilljebjörn; Carl Högberg; Anna Hagström-Andersson; Thoas Fioretos; Jonas Larsson; Marcus Järås
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

Review 6.  BCMA-targeted immunotherapy for multiple myeloma.

Authors:  Bo Yu; Tianbo Jiang; Delong Liu
Journal:  J Hematol Oncol       Date:  2020-09-17       Impact factor: 17.388

Review 7.  B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.

Authors:  Shirin Teymouri Nobari; Jafar Nouri Nojadeh; Mehdi Talebi
Journal:  J Transl Med       Date:  2022-02-10       Impact factor: 5.531

Review 8.  Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.